Coverage
-
August 03, 2018
A certified class of investors in Juno Therapeutics told a Washington federal judge on Thursday that it has reached a $24 million settlement to resolve claims that the biopharmaceutical company's failure to disclose the death of one of its immunotherapy patients led to a 30 percent drop in its share price.
1 other articles on this case.
View all »